XORTX Therapeutics Inc. (“XORTX” or the “Company“) (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU))))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce positive topline results from the XRX-OXY-101 – Bridging Pharmacokinetics Clinical Trial (the “Study“) characterizing the pharmacokinetics of the Company’s proprietary formulation of oral oxypurinol, XORLOTM. Results from the Study showed that XORLOTM was well tolerated across the various dosing regimens. No safety issues were identified in any of the four parts of the Study on the 88 subjects who received drug. Results from the four parts of the Study showed (i) a substantial increase in the bioavailability of oxypurinol with the XORLOTM formulation platform; (ii) increased dose proportionality compared to non-formulated oxypurinol; (iii) a multiple dosing regimen that achieved therapeutic target values; and (iv) confirmation of the innovations claimed in the recently granted US and EU patents regarding the Company’s unique proprietary formulations of oxypurinol.
ImmunityBio Offers Update On Status Of Its Biologics License Application For VesAnktiva
ImmunityBio, Inc. (NASDAQ:IBRX), a clinical-stage immunotherapy company, today announced that it has achieved a major milestone with over 80 subjects in the QUILT-3.032 study completing at least 12 months of follow-up as
